Patient characteristics (age, gender, comorbidities), clinical follow up, including a multidisciplinary clinical diagnosis, if applicable, and RT-PCR results were extracted from electronic patient records. These data allowed stratification of all patients into one of the following three groups: patients with at least one positive RT-PCR result for SARS-CoV-2 within five days after CT (PCR+), patients with one or multiple negative RT-PCR results but a clinical diagnosis of COVID-19 according to clinical records (PCR-/Clinical+), and patients with one or multiple negative RT-PCR results and a clinical course not consistent with COVID-19, or consistent with an alternative diagnosis (PCR-/Clinical-).
Radiotherapy
It involves the use of high-energy radiation, such as X-rays, gamma rays, or charged particles, to target and destroy cancer cells while minimizing damage to surrounding healthy tissue.
The goal of radiotherapy is to deliver the most effective radiation dose to the tumor site while sparing normal tissues.
Radiotherapy can be used as a primary treatment, in combination with other therapies (such as chemotherapy or surgery), or as a palliative measure to alleviate symptoms.
The field of radiotherapy is constantly evolving, with new techniques, technologies, and protocols being developed to enhance the precision, safety, and efficacy of this treatment approach.
Understanding the latest advancements in radiotherapy is essential for healthcare professionals and researchers working to improve patient outcomes.
Most cited protocols related to «Radiotherapy»
Patient characteristics (age, gender, comorbidities), clinical follow up, including a multidisciplinary clinical diagnosis, if applicable, and RT-PCR results were extracted from electronic patient records. These data allowed stratification of all patients into one of the following three groups: patients with at least one positive RT-PCR result for SARS-CoV-2 within five days after CT (PCR+), patients with one or multiple negative RT-PCR results but a clinical diagnosis of COVID-19 according to clinical records (PCR-/Clinical+), and patients with one or multiple negative RT-PCR results and a clinical course not consistent with COVID-19, or consistent with an alternative diagnosis (PCR-/Clinical-).
Of the 750 tumor samples of the CIT cohort, 566 fulfilled RNA quality requirements for GEP analysis (
Most recents protocols related to «Radiotherapy»
Example 9
A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.
Example 6
An adult patient with rhabomyosarcoma is treated with IV Vincristine at a dose of 1.4 mg/m2. Concomitantly the patient is administered 0.1 cc kg of DDFPc while breathing room air. Despite breathing room air, increased oxygen levels am still attained in the tumor tissue resulting in increased activity of the drug.
Example 3
At the time of diagnosis with prostate cancer, subjects are invited to participate in a trial. A subject sample, e.g., blood, is obtained. Periodically, throughout the monitoring, watchful waiting, or active treatment of the subject, e.g., chemotherapy, radiation therapy, e.g., radiation of the prostate, surgery, e.g., surgical prostate resection, hormone therapy, a new subject sample is obtained. At the end of the study, all subject samples are tested for the level of FLNA and/or PSA, and optionally other markers. The subject samples are matched to the medical records of the subjects to correlate FLNA and/or PSA levels, as appropriate, with prostate cancer status at the time of diagnosis, rate of progression of disease, response of subjects to one or more interventions, and transitions between androgen dependent and independent status. Other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA.
Example 2
A 30 year-old female subject with muscle pain in the left leg and joint pain in near the left ankle—is positioned in a 360-degree full body light therapy device. The 360-degree light therapy device is configured as follows: (a) a first type of light emitting diode (LED) emits a wavelength of 550 nm, (b) a second type of LED emits a wavelength of 750 nm, (c) a third type of LED emits a wavelength of about 850 nm, and (d) a fourth type of LED emits a wavelength of about 900 nm.
The light therapy device has: 11520 first LED types (about 25.6% of the total LEDs), 5760 second LED types (about 12.8% of the total LEDs), 21960 third LED types (about 48.8% of the total LEDs), and 11520 fourth LED types (about 25.6% of the total LEDs). The LEDs emit with a power density of about 80 mW/cm2. The LEDs emit power at about 50 Joules/cm2 in a time period of about 10 minutes. The light therapy device is configured to pulse at a rate of about 10 hertz with an 85% duty cycle.
The subject undergoes a 30-minute session of irradiation twice a month for 3 straight months. After the 3 months of treatment, the subject's muscle pain in the left leg mitigates by about 80%, and the subject's joint pain near the left ankle reduces by about 50%.
Example 3
A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.
Top products related to «Radiotherapy»
More about "Radiotherapy"
This powerful therapeutic approach involves the use of high-energy radiation, such as X-rays, gamma rays, or charged particles, to target and destroy cancer cells while minimizing damage to surrounding healthy tissue.
The primary goal of radiotherapy is to deliver the most effective radiation dose to the tumor site while sparing normal tissues, ultimately enhancing patient outcomes.
The field of radiotherapy is constantly evolving, with new techniques, technologies, and protocols being developed to improve the precision, safety, and efficacy of this treatment approach.
Healthcare professionals and researchers working in this domain must stay up-to-date with the latest advancements to provide the best possible care for their patients.
One cutting-edge technology used in radiotherapy is the X-RAD 320, a state-of-the-art irradiation system that enables precise and targeted delivery of radiation.
Additionally, the use of RPMI 1640 medium and DMEM (Dulbecco's Modified Eagle Medium) in cell culture experiments can provide valuable insights into the biological effects of radiation on cancer cells, complementing the clinical research on radiotherapy.
Data analysis tools such as SAS version 9.4 and MATLAB can also play a crucial role in radiotherapy research, allowing researchers to analyze complex datasets, model treatment outcomes, and optimize protocols.
Furthermore, the implementation of AI-driven platforms like PubCompare.ai can help identify the most effective radiotherapy protocols and products, enhancing reproducibility and accuracy in this field.
Whether used as a primary treatment, in combination with other therapies like chemotherapy or surgery, or as a palliative measure to alleviate symptoms, radiotherapy remains a cornerstone of modern cancer management.
By staying informed about the latest advancements and leveraging the power of cutting-edge technologies and data analysis tools, healthcare professionals and researchers can continue to improve the lives of patients facing a wide range of medical conditions.